Profile data is unavailable for this security.
About the company
Zentek Ltd. is an intellectual property technology company. The Company is focused primarily on commercializing ZenGUARD, as well as on the development of certain aptamer technologies and other nanomaterials-based technologies. ZenGUARD is the Company’s patented anti-microbial coating technology platform. Its platform, ZenGUARD, has been shown to have enhanced bacterial and viral filtration efficiency for surgical masks and heating, ventilation, and air conditioning (HVAC) systems. The Company is also focused on the research, development and commercialization of novel products, seeking to give the Company's commercial partners a competitive advantage by making their products better, safer, and greener. The Company has installed industrial-scale production equipment to produce the ZenGUARD coating formulation. The Company is also working on developing processes to synthesize graphene, GO and graphene quantum dots, along with other possible applications for graphene-based materials.
- Revenue in CAD (TTM)915.32k
- Net income in CAD-8.19m
- Incorporated2008
- Employees17.00
- LocationZentek Ltd24 Corporate CtGUELPH N1G 5G5CanadaCAN
- Phone+1 (705) 618-0900
- Fax+1 (705) 618-0900
- Websitehttps://www.zentek.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ZYUS Life Sciences Corp | 465.00k | -33.74m | 48.36m | 2.00 | -- | -- | -- | 104.01 | -0.4505 | -0.4505 | 0.0062 | -0.1659 | 0.0208 | 0.3346 | 1.17 | -- | -150.55 | -74.90 | -454.68 | -102.81 | 13.12 | 3.61 | -7,256.77 | -8,974.20 | 0.0726 | -9.28 | 6.94 | -- | 37.04 | 313.06 | 20.63 | -- | -- | -- |
| Nurexone Biologic Inc | 0.00 | -8.85m | 58.02m | 9.00 | -- | 26.72 | -- | -- | -0.1189 | -0.1189 | 0.00 | 0.0239 | 0.00 | -- | -- | -- | -208.79 | -215.30 | -263.35 | -529.63 | -- | -- | -- | -- | -- | -102.73 | 0.0514 | -- | -- | -- | -38.58 | -- | -- | -- |
| Medicenna Therapeutics Corp | 0.00 | -13.82m | 65.89m | 18.00 | -- | 6.43 | -- | -- | -0.1696 | -0.1696 | 0.00 | 0.1228 | 0.00 | -- | -- | 0.00 | -54.21 | -56.44 | -63.31 | -63.20 | -- | -- | -- | -- | -- | -- | 0.0143 | -- | -- | -- | 53.64 | -- | -- | -- |
| Sharp Therapeutics Corp | 0.00 | -9.19m | 66.01m | -- | -- | 34.40 | -- | -- | -4.11 | -4.11 | 0.00 | 0.0639 | 0.00 | -- | -- | -- | -435.86 | -- | -512.62 | -- | -- | -- | -- | -- | -- | -- | 0.477 | -- | -- | -- | -2,282.81 | -- | -- | -- |
| Zentek Ltd | 915.32k | -8.19m | 94.62m | 17.00 | -- | 7.89 | -- | 103.37 | -0.0785 | -0.0785 | 0.0088 | 0.1115 | 0.048 | 0.4823 | 5.22 | 53,842.35 | -42.98 | -56.35 | -50.88 | -61.72 | 48.68 | -83.98 | -895.31 | -5,414.02 | 0.5344 | -- | 0.1391 | -- | 2,825.89 | -- | 14.22 | -- | -35.15 | -- |
| Helix Biopharma Corp | 0.00 | -4.88m | 140.54m | 7.00 | -- | 8.75 | -- | -- | -0.0833 | -0.0833 | 0.00 | 0.2104 | 0.00 | -- | -- | -- | -50.07 | -166.45 | -66.34 | -430.79 | -- | -- | -- | -- | -- | -24.39 | 0.0214 | -- | -- | -- | 43.81 | -- | -34.02 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Scotia Capital, Inc. (Broker)as of 30 Sep 2025 | 881.20k | 0.82% |
| RBC Dominion Securities, Inc. (Investment Management)as of 30 Sep 2025 | 271.43k | 0.25% |
| Desjardins Securities, Inc.as of 30 Sep 2025 | 147.18k | 0.14% |
| CIBC World Markets, Inc.as of 30 Sep 2025 | 141.25k | 0.13% |
| BMO Asset Management, Inc.as of 30 Sep 2025 | 56.46k | 0.05% |
| Geode Capital Management LLCas of 31 Dec 2025 | 53.85k | 0.05% |
| Renaissance Technologies LLCas of 30 Sep 2025 | 38.10k | 0.04% |
| Creative Planning LLCas of 30 Sep 2025 | 30.35k | 0.03% |
| AQR Capital Management LLCas of 30 Sep 2025 | 30.35k | 0.03% |
| TD Waterhouse Canada, Inc.as of 31 Dec 2025 | 29.18k | 0.03% |
